Clinical trial
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic…
NCT00199030 · Goethe University, Other · Completed
Key facts
| NCT number | NCT00199030 |
|---|---|
| Title | Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath |
| Official title | German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure |
| Lead sponsor | Goethe University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic |
| Intervention type | Drug |
| Interventions | Alemtuzumab (MabCampath), Cladribine |
| Enrollment | 8 |
| Start date | Feb 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 20, 2023 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: